Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement (NCT07526870) | Clinical Trial Compass
CompletedNot Applicable
Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement
Mexico30 participantsStarted 2024-07-24
Plain-language summary
This study aims to evaluate the efficacy and safety of microdoses of botulinum toxin type A (microtoxin) for improving periocular skin quality and reducing fine wrinkles. Botulinum toxin is commonly used in aesthetic medicine; however, its use in microdoses has been proposed to achieve more natural results with fewer adverse effects.
Participants with periocular rhytids will receive intradermal injections of diluted botulinum toxin. Clinical outcomes will include improvement in skin texture, wrinkle reduction, and patient satisfaction. Safety will be assessed by monitoring adverse events.
The findings of this study may help determine whether microtoxin is an effective and safe option for minimally invasive periocular rejuvenation.
Who can participate
Age range
18 Years – 35 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged 18 to 35 years
* Both male and female participants
* Presence of mild to moderate periocular fine wrinkles
* Willingness to undergo intradermal botulinum toxin injections
* Ability to provide written informed consent
Exclusion Criteria:
* Previous botulinum toxin treatment in the periocular area within the last 6 months
* Known hypersensitivity to botulinum toxin or its components
* Active skin infection or dermatologic disease in the treatment area
* Neuromuscular disorders
* Pregnancy or breastfeeding
* Use of medications affecting neuromuscular transmission
* History of eyelid or periocular surgery within the last 6 months
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in sebum production (mm²) from baseline to 6 weeks after intradermal botulinum toxin type A treatment
Timeframe: Baseline and 6 weeks after treatment
Trial details
NCT IDNCT07526870
SponsorInstituto de Oftalmología Fundación Conde de Valenciana